<?xml version="1.0" encoding="utf-8"?>
<!-- generator="FeedCreator 1.7.2-ppt (info@mypapit.net)" -->
<?xml-stylesheet href="http://ctaf.org/feed.css" type="text/css"?>
<?xml-stylesheet href="http://ctaf.org/feed-atom.xsl" type="text/xsl"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <title>California Technology Assessment Forum</title>
    <subtitle>California Technology Assessment Forum</subtitle>
    <link rel="alternate" type="text/html" href="http://ctaf.org/"/>
    <id>http://ctaf.org/</id>
    <updated>2010-03-12T15:51:57+00:00</updated>
    <generator>FeedCreator 1.7.2-ppt (info@mypapit.net)</generator>
<link rel="self" type="application/atom+xml" href="http://ctaf.org/atom.xml" />
    <entry>
        <title>Transurethral Microwave Thermotherapy for the Treatment of Benign Prostatic Hyperplasia</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/assessment/detail/1075/"/>
        <published>2009-10-29T02:15:00+00:00</published>
        <updated>2009-10-29T02:15:00+00:00</updated>
        <id>http://ctaf.org/content/assessment/detail/1075/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
        <summary>It is recommended that transurethral microwave thermotherapy meets CTAF criteria 1-5 for safety, effectiveness and improvement in health outcomes for the treatment of benign prostatic hyperplasia in men with moderately severe obstructive symptoms and prostate volume of 30-100mL, with no history of prostate procedures, and without prostate cancer.</summary>
    </entry>
    <entry>
        <title>Extracorporeal Shockwave Therapy (ESWT) for Plantar Fasciitis not Responding to Conservative Therapy</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/assessment/detail/1074/"/>
        <published>2009-10-29T02:15:00+00:00</published>
        <updated>2009-10-29T02:15:00+00:00</updated>
        <id>http://ctaf.org/content/assessment/detail/1074/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
        <summary>It is recommended that the use of ESWT for the treatment of plantar fasciitis does not meet technology assessment criteria 3, 4, or 5 for safety, effectiveness, and improvement in health outcomes.</summary>
    </entry>
    <entry>
        <title>Artificial Disc Replacement for Degenerative Disc Disease of the Cervical Spine</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/assessment/detail/1073/"/>
        <published>2009-10-29T02:15:00+00:00</published>
        <updated>2009-10-29T02:15:00+00:00</updated>
        <id>http://ctaf.org/content/assessment/detail/1073/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
        <summary>It is recommended that cervical disc replacement as an alternative to spinal fusion does not meet CTAF criteria 3-5 for improvement in health outcomes.</summary>
    </entry>
    <entry>
        <title>Laparoscopic Adjustable Silicone Gastric Banding for Obesity</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/assessment/detail/1072/"/>
        <published>2009-10-29T02:15:00+00:00</published>
        <updated>2009-10-29T02:15:00+00:00</updated>
        <id>http://ctaf.org/content/assessment/detail/1072/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
        <summary>It is recommended that the use of LAGB for the treatment of obesity meets CTAF technology assessment criteria 1 through 5 for safety, effectiveness and improvement in health outcomes.</summary>
    </entry>
    <entry>
        <title>CTAF Meeting</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/calendar/detail/1049/"/>
        <published>2009-10-13T04:00:00+00:00</published>
        <updated>2009-10-13T04:00:00+00:00</updated>
        <id>http://ctaf.org/content/calendar/detail/1049/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
    </entry>
    <entry>
        <title>CTAF Meeting</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/calendar/detail/1048/"/>
        <published>2009-10-13T04:00:00+00:00</published>
        <updated>2009-10-13T04:00:00+00:00</updated>
        <id>http://ctaf.org/content/calendar/detail/1048/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
    </entry>
    <entry>
        <title>CTAF Meeting</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/calendar/detail/1047/"/>
        <published>2009-10-12T03:45:00+00:00</published>
        <updated>2009-10-12T03:45:00+00:00</updated>
        <id>http://ctaf.org/content/calendar/detail/1047/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
    </entry>
    <entry>
        <title>Andrew Robertson, MD, MMM</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/member/detail/1041/"/>
        <published>2009-10-02T23:00:00+00:00</published>
        <updated>2009-10-02T23:00:00+00:00</updated>
        <id>http://ctaf.org/content/member/detail/1041/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
    </entry>
    <entry>
        <title>Hypofractionated Whole Breast Radiation Therapy Following Breast- conserving Surgery</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/assessment/detail/1039/"/>
        <published>2009-03-11T22:30:00+00:00</published>
        <updated>2009-03-11T22:30:00+00:00</updated>
        <id>http://ctaf.org/content/assessment/detail/1039/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
        <summary>It is recommended that the use of hypofractionation meets CTAF technology assessment criteria 1 through 5 for safety, effectiveness and improvement in health outcomes when used as adjuvant radiation therapy following breast surgery for localized breast cancer in the fully informed patient.</summary>
    </entry>
    <entry>
        <title>Portable Devices Used in Home Testing for Obstructive Sleep Apnea</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/assessment/detail/1038/"/>
        <published>2009-03-11T22:30:00+00:00</published>
        <updated>2009-03-11T22:30:00+00:00</updated>
        <id>http://ctaf.org/content/assessment/detail/1038/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
        <summary>It is recommended that the use of two portable home devices (Remmers Sleep Recorder, WatchPat) to diagnose OSA meets technology assessment criteria 1 through 5 for safety, effectiveness and improvement in health outcomes in patients at very high risk for OSA and unlikely to have another cause for their sleepiness.</summary>
    </entry>
    <entry>
        <title>Repetitive Transcranial Magnetic Stimulation for Treatment Resistant Depression</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/assessment/detail/1028/"/>
        <published>2009-06-18T03:15:00+00:00</published>
        <updated>2009-06-18T03:15:00+00:00</updated>
        <id>http://ctaf.org/content/assessment/detail/1028/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
        <summary>It is recommended that repetitive transcranial magnetic stimulation does not meet CTAF TA criteria 3-5 for efficacy and improvement in health outcomes in patients with treatment resistant depression.</summary>
    </entry>
    <entry>
        <title>Assessing Cardiovascular Disease Risk with hs C-reactive Protein</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/assessment/detail/1027/"/>
        <published>2009-06-18T03:15:00+00:00</published>
        <updated>2009-06-18T03:15:00+00:00</updated>
        <id>http://ctaf.org/content/assessment/detail/1027/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
        <summary>It is recommended that measurement of hs-CRP does not meet CTAF criteria 3--5 for effectiveness and improvement in health outcomes compared with no testing.</summary>
    </entry>
    <entry>
        <title>Carotid Artery Stenting</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/assessment/detail/1026/"/>
        <published>2009-06-18T03:15:00+00:00</published>
        <updated>2009-06-18T03:15:00+00:00</updated>
        <id>http://ctaf.org/content/assessment/detail/1026/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
        <summary>It is recommended that carotid artery angioplasty with stenting does not meet CTAF TA criteria 3 through 5 for improvement in health outcomes.</summary>
    </entry>
    <entry>
        <title>Balloon Kyphoplasty as a Treatment for Vertebral Compression Fractures</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/assessment/detail/1025/"/>
        <published>2009-06-18T03:15:00+00:00</published>
        <updated>2009-06-18T03:15:00+00:00</updated>
        <id>http://ctaf.org/content/assessment/detail/1025/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
        <summary>It is recommended that balloon kyphoplasty with PMMA meets CTAF criteria 1-5 for safety, effectiveness and improvement in health outcomes for the treatment of recent (&lt; 3mo. old) osteoporotic vertebral compression fractures confirmed by MRI.

It is further recommended that balloon kyphoplasty does not meet CTAF criteria 3-5 for effectiveness and improvement in health outcomes for the treatment of chronic (&gt;3mo.old) osteoporotic, traumatic or pathologic vertebral compression fractures.</summary>
    </entry>
    <entry>
        <title>Computed Tomography Colonography (Virtual Colonoscopy) for Colorectal Cancer Screening in Average Risk Individuals</title>
        <link rel="alternate" type="text/html" href="http://ctaf.org/content/assessment/detail/989/"/>
        <published>2009-03-11T04:00:00+00:00</published>
        <updated>2009-03-11T04:00:00+00:00</updated>
        <id>http://ctaf.org/content/assessment/detail/989/</id>
        <author>
            <name>California Technology Assessment Forum</name>
        </author>
        <summary>It is recommended that CTC does not meet CTAF TA criteria 3, 4 or 5 as a screening test for CRC in average risk individuals.</summary>
    </entry>
</feed>
